uniQure NVMEX:QUREN 29 Median PS Value is MXN117.31 as of Jun. 27, 2026, which is 100% below its 10-year median of 1.12. GuruFocus rates MEX:QUREN with a GF Score™ of 29/100 and a GF Value™ of MXN99.43 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 276 Biotechnology companies, uniQure NV ranks worse than 97.1% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. uniQure NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN5.6. uniQure NV's 10-Year median PS Ratio is 20.9482. Therefore, the Median PS Value for today is MXN117.31.
As of today (2026-06-27), uniQure NV's share price is MXN795.45. uniQure NV's Median PS Value is MXN117.31. Therefore, uniQure NV's Price to Median PS Value for today is 6.78.
The historical rank and industry rank for uniQure NV's Median PS Value or its related term are showing as below:
MEX:QUREN'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08 Med: 1.12 Max: 8.57
Current: 6.78
During the past 13 years, the highest Price to Median PS Value of uniQure NV was 8.57. The lowest was 0.08. And the median was 1.12.
MEX:QUREN's Price-to-Median-PS-Value is ranked worse than 97.1% of 276
companies
in the Biotechnology industry
Industry Median: 0.62
vs MEX:QUREN: 6.78
uniQure NV (MEX:QUREN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
uniQure NV's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
795.45
/
117.31
=
6.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV Median PS Value Related Terms
uniQure NV Median PS Value Historical Data
* Premium members only.
The historical data trend for uniQure NV's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:QUREN vs NVAX, HRMY, IOVA: Median PS Value Comparison
For the Biotechnology subindustry, uniQure NV's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where uniQure NV's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 20.9482.
uniQure NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN5.6.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (MEX:QUREN) has a Median PS Value of MXN117.31 as of Jun. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on uniQure NV and its competitors. This is 10374% above median its historical median of 1.12. Over the past decade, uniQure NV's Median PS Value has ranged from 0.08 to 8.57. According to the industry distribution chart, uniQure NV ranks #268 out of 276 companies in the Biotechnology industry, placing it in the top 97.1%.
Is uniQure NV's Median PS Value too high?
uniQure NV's current Median PS Value of MXN117.31 is 10374% above median its 10-year median of 1.12. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 8.57. Based on the distribution chart, uniQure NV ranks #268 out of 276 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, uniQure NV has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Median PS Value compare to NVAX and HRMY?
According to the Biotechnology industry distribution chart, uniQure NV ranks #268 out of 276 companies for Median PS Value. This places uniQure NV in the lower half of its industry. The industry median Median PS Value is 0.62. Historically, uniQure NV's own Median PS Value has ranged from 0.08 to 8.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on uniQure NV and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current Median PS Value is MXN117.31, which is 10374% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (MEX:QUREN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN99.43, compared to a current price of MXN795.45 — trading 700% above its estimated fair value. The current Median PS Value is MXN117.31, which is 10374% above median its 10-year median of 1.12. uniQure NV's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For uniQure NV (MEX:QUREN), the current Median PS Value is MXN117.31 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (MEX:QUREN) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of MXN795.45 is trading 700% above its estimated GF Value™ of MXN99.43.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for MEX:QUREN:
Median PS Value: MXN117.31 (10374% above median its 10-year median of 1.12)
GF Value™: MXN99.43 vs. price of MXN795.45 (700% above fair value)
No single metric tells the full story. See the MEX:QUREN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
29GF Score
Get the complete analysis for MEX:QUREN
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:QUREN has been successfully added to your 
